Latest Rewards And Loyalty News

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

Mount Hope Mining Limited has announced a non-renounceable pro-rata Loyalty Option Offer to raise approximately $103,125, aiming to bolster exploration funding and reward shareholder loyalty.

Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.

My Rewards International Limited reports steady progress on its B2B rewards platform and the soft launch of its Klevo MasterCard, while navigating ongoing ASX suspension and securing a $15 million financing facility.